CM
REGN icon

Capula Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Capula Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-181
Closed -$123K – 911
2025
Q3 		$102K Sell
181
-59
-25% -$33.4K ﹤0.01% 718
2025
Q2 		$126K Buy
240
+49
+26% +$27.3K ﹤0.01% 471
2025
Q1 		$121K Buy
+191
New +$131K ﹤0.01% 601
2024
Q4 		– Sell
-34
Closed -$35.7K – 567
2024
Q3 		$35.7K Buy
+34
New +$37.8K ﹤0.01% 470
2024
Q2 		– Sell
-62
Closed -$59.7K – 621
2024
Q1 		$59.7K Sell
62
-431
-87% -$410K ﹤0.01% 449
2023
Q4 		$433K Sell
493
-39
-7% -$32.1K 0.02% 157
2023
Q3 		$438K Buy
+532
New +$418K 0.01% 405
2021
Q2 		– Sell
-9,286
Closed -$4.39M – 857
2021
Q1 		$4.39M Buy
+9,286
New +$4.52M 0.09% 224

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capula Management's REGN Position: Q4 2025 in Review

Capula Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 181 shares — an estimated $123K sold.

Capula Management first reported a position in REGN in Q1 2021 and held it in 8 quarters. The position peaked at $4.39M in Q1 2021. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Capula Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capula Management sold 181 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $123K.
  • Capula Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Capula Management's Regeneron Pharmaceuticals position peaked at $4.39M in Q1 2021.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Capula Management's 13F filing for Q4 2025, filed 13 Feb 2026.